^
    Back
    Association details:
    Biomarker:IDH1 wild-type + BRAF mutation
    Cancer:Glioma
    Drug:Mekinist (trametinib) (MEK inhibitor) +
    Tafinlar (dabrafenib) (BRAF inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Front Med (Lausanne)
    Title:

    Druggable genomic landscapes of high-grade gliomas

    Published date:
    12/25/2023
    Excerpt:
    Among the JH MTB cohort of patients with IDH1 wild-type high-grade gliomas who received targeted therapies, trametinib monotherapy or in combination with dabrafenib conferred radiographic partial response in 75% of patients harboring BRAF or NF1 actionable mutations.
    DOI:
    10.3389/fmed.2023.1254955